Identification of clinical, epidemiological and laboratory risk factors for leprosy reactions during and after multidrug therapy
AUTOR(ES)
Antunes, Douglas Eulálio, Araujo, Sergio, Ferreira, Gabriela Porto, Cunha, Ana Carolina Sousa Rodrigues da, Costa, Adeilson Vieira da, Gonçalves, Maria Aparecida, Goulart, Isabela Maria Bernardes
FONTE
Mem. Inst. Oswaldo Cruz
DATA DE PUBLICAÇÃO
2013-11
RESUMO
This cross-sectional retrospective study evaluated 440 leprosy patients; 57% (251/440) had leprosy reactions during and/or after multidrug therapy, 80.5% (202/251) of whom presented with multibacillary leprosy. At diagnosis, positive bacterial index (BI) [odds ratio (OR) = 6.39; 95% confidence interval (CI): 4.1-10.1)] or polymerase chain reaction (PCR) (OR = 9.15; 95% CI: 5.4-15.5) in skin smears, anti-phenolic glycolipid-1 (anti-PGL-1) ELISA (OR = 4.77; 95% CI: 2.9-7.9), leucocytosis (OR = 9.97; 95% CI: 3.9-25.7), thrombocytopenia (OR = 5.72; 95% CI: 2.3-14.0) and elevated lactate dehydrogenase (OR = 2.38; 95% CI: 1.4-4.0) were potential markers for the development of reactions during treatment. After treatment, positive BI (OR = 8.47; 95% CI: 4.7-15.3) and PCR (OR = 6.46; 95% CI: 3.4-12.3) in skin smears, anti-PGL-1 ELISA (OR = 2.25; 95% CI: 1.3-3.9), anaemia (OR = 2.36; 95% CI: 1.2-4.5), leucocytosis (OR = 4.14; 95% CI: 1.5-11.6) and thrombocytopenia (OR = 3.70; 95% CI: 1.3-2.2) were risk factors for the occurrence of reactions during the study period. The identification of groups with an increased risk for developing reactions will allow for the timely development of a treatment plan to prevent nerve damage and, therefore, the appearance of the disabling sequelae associated with the stigma of leprosy.
Documentos Relacionados
- Caracterização clínica, epidemiológica e laboratorial das reações hansênicas durante e após poliquimioterapia: análise de potenciais fatores preditivos
- Number of leprosy reactions during treatment: clinical correlations and laboratory diagnosis
- Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients
- Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci.
- Mycetomas: an epidemiological, etiological, clinical, laboratory and therapeutic review